Project description
Innovative platform for precision drug repurposing
Drug repurposing investigates the use of existing drugs for new therapeutic purposes. Thus, it reduces the time and costs of drug development. However, it is often accidental and less effective than classical drug discovery. Both discovery and repurposing suffer from the same knowledge gap, whereby diseases are not understood from a mechanistic perspective and are treated symptomatically in an imprecise manner. The EU-funded REPO4EU project will establish a comprehensive European/global platform for validated precision drug repurposing open to stakeholders for information, multimedia training, matchmaking and cooperation. The project, consisting of world-leading scientists, will redefine diseases using a mechanism-based approach, applying advanced bioinformatics and AI to real-world Big Data.
Objective
Here we, a group of long-standing collaborators in innovative drug repurposing, propose to build REPO4EU, a comprehensive European/global platform for validated precision drug repurposing open to stakeholders for information, multimedia training, matchmaking and cooperation. Drug repurposing reduces the time and costs of drug development but is often serendipitous and less effective than classical drug discovery. Both, discovery and repurposing, suffer from the same knowledge gap that diseases are mechanistically not understood and treated symptomatically in an imprecise manner. Our team of world-leading scientists overcome this by breakthroughs in advanced bioinformatics and artificial intelligence (AI) on real-world big data to redefine diseases in a mechanism-based manner. Patients are still identified by symptom, but stratified according to causal mechanism, the endotype. Trials are small, precise, innovatively designed, prioritising, in coordination with regulators, payers and investors, patient-defined outcomes with high safety and operational excellence. This revolutionary new era of medicine will allow unprecedented efficacy and cost-effectiveness. The promiscuity of small molecules and recently expanded knowledge of protein structures are exploited by cheminformatics and deep learning to repurpose drugs beyond their original target. At any level of the development chain, even for classic projects, REPO4EU provides expertise and matchmaking for freedom-to-operate, intellectual property, reformulation and value-creation, specialised in drug repurposing. Within 5 years, REPO4EU will establish a first-in-class coherent and innovative web-based platform for safe and efficient drug repurposing for all types of high unmet medical need indications to all European researchers and SMEs with a unique Open Science concept, ensuring global medical impact. Finally, within a 2-year interphase, REPO4EU will be converted into a sustainable European infrastructure.
Fields of science
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencescomputer and information sciencesdata sciencebig data
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencescomputer and information sciencesartificial intelligencemachine learningdeep learning
Keywords
Programme(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
6200 MD Maastricht
Netherlands
See on map
Participants (27)
Participation ended
82256 FURSTENFELDBRUCK
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
1010 Wien
See on map
80333 Munchen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
08039 Barcelona
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20148 Hamburg
See on map
80333 Muenchen
See on map
13353 Berlin
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
69151 Neckargemund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28040 Madrid
See on map
73529 Schwabisch Gmund
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
See on map
362 91 Tingsryd
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
28005 MADRID
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
104 22 Stockholm
See on map
02115 BOSTON MA
See on map
53127 Bonn
See on map
1170 Wien
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4818 CL Breda
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
520014 Sfantu Gheorghe
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
5026 SK Tilburg
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
6525 GA Nijmegen
See on map
6229 HX Maastricht
See on map
10437 Berlin
See on map
9000 Gent
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
4099-002 Porto
See on map
1181 VX Amstelveen
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
10117 BERLIN
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Partners (1)
Partner organisations contribute to the implementation of the action, but do not sign the Grant Agreement.
8006 Zurich
See on map